JP2020507587A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507587A5
JP2020507587A5 JP2019543800A JP2019543800A JP2020507587A5 JP 2020507587 A5 JP2020507587 A5 JP 2020507587A5 JP 2019543800 A JP2019543800 A JP 2019543800A JP 2019543800 A JP2019543800 A JP 2019543800A JP 2020507587 A5 JP2020507587 A5 JP 2020507587A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
subject
aureus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019543800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507587A (ja
JP7145162B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/000209 external-priority patent/WO2018150265A1/en
Publication of JP2020507587A publication Critical patent/JP2020507587A/ja
Publication of JP2020507587A5 publication Critical patent/JP2020507587A5/ja
Priority to JP2022147604A priority Critical patent/JP2022188083A/ja
Application granted granted Critical
Publication of JP7145162B2 publication Critical patent/JP7145162B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019543800A 2017-02-16 2018-02-16 化膿性汗腺炎の処置 Active JP7145162B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022147604A JP2022188083A (ja) 2017-02-16 2022-09-16 化膿性汗腺炎の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459841P 2017-02-16 2017-02-16
US62/459,841 2017-02-16
PCT/IB2018/000209 WO2018150265A1 (en) 2017-02-16 2018-02-16 Treatment of hidradenitis suppurativa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022147604A Division JP2022188083A (ja) 2017-02-16 2022-09-16 化膿性汗腺炎の処置

Publications (3)

Publication Number Publication Date
JP2020507587A JP2020507587A (ja) 2020-03-12
JP2020507587A5 true JP2020507587A5 (enExample) 2021-03-25
JP7145162B2 JP7145162B2 (ja) 2022-09-30

Family

ID=63170129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019543800A Active JP7145162B2 (ja) 2017-02-16 2018-02-16 化膿性汗腺炎の処置
JP2022147604A Pending JP2022188083A (ja) 2017-02-16 2022-09-16 化膿性汗腺炎の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022147604A Pending JP2022188083A (ja) 2017-02-16 2022-09-16 化膿性汗腺炎の処置

Country Status (12)

Country Link
US (5) US11225517B2 (enExample)
EP (1) EP3582813A4 (enExample)
JP (2) JP7145162B2 (enExample)
KR (1) KR20190117579A (enExample)
CN (1) CN110382001A (enExample)
AU (1) AU2018220862A1 (enExample)
CA (1) CA3053231A1 (enExample)
IL (1) IL268569A (enExample)
MX (1) MX2019009798A (enExample)
PH (1) PH12019501900A1 (enExample)
SG (1) SG11201907159SA (enExample)
WO (1) WO2018150265A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110311547A1 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis Treatment
KR20210128021A (ko) 2010-08-23 2021-10-25 얀센 바이오테크 인코포레이티드 종양성 질병들에 대한 치료
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
TWI737000B (zh) * 2018-10-22 2021-08-21 美商美國禮來大藥廠 用於治療化膿性汗腺炎之泛-elr+cxc趨化介素抗體
AU2020228299A1 (en) * 2019-02-28 2021-09-09 Janssen Biotech, Inc. Anti-IL-alpha antibody for the treatment of hidradenitis suppurativa
CA3179228A1 (en) * 2020-04-16 2021-10-21 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
US20230293544A1 (en) * 2022-03-17 2023-09-21 Pfizer Inc. Methods, dosage regimens, and compositions for treating hidradenitis

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5407431A (en) 1989-07-11 1995-04-18 Med-Design Inc. Intravenous catheter insertion device with retractable needle
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
AU5355094A (en) 1992-10-14 1994-05-09 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
DE19943790C2 (de) 1999-09-13 2001-11-15 Ericsson Telefon Ab L M Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten
US6380129B1 (en) 1999-11-02 2002-04-30 Richard J. Kraemer Enhanced materials for treatment of contamination
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
JPWO2002033094A1 (ja) 2000-10-19 2004-10-21 協和醗酵工業株式会社 Vplfの活性を阻害する抗体
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
AU2003208415B2 (en) 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Amf類を有効成分とする医薬製剤
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
KR100493102B1 (ko) 2003-06-30 2005-06-02 삼성전자주식회사 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
CA2568352C (en) * 2004-06-04 2011-09-13 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
US8603483B2 (en) 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses
DK1915620T3 (da) 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
AU2006298767B2 (en) 2005-09-28 2013-01-10 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof
EP2021026A1 (en) 2006-04-14 2009-02-11 Novartis AG Use of il-i antibodies for treating ophthalmic disorders
EP2021033B1 (en) 2006-05-15 2012-03-28 XBiotech, Inc Il-1-alpha for use in a method of treatment of atherosclerotic plaques.
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
WO2007135546A2 (en) 2006-05-22 2007-11-29 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
JP2009538629A (ja) 2006-05-30 2009-11-12 ジェネンテック・インコーポレーテッド 抗体およびイムノコンジュゲートとこれらの使用方法
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
WO2009128934A1 (en) 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
PL3085773T3 (pl) 2008-05-30 2021-01-11 Xbiotech, Inc Zastosowanie przeciwciał il-1 alfa
JP5976319B2 (ja) 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
BRPI0920354A2 (pt) 2008-10-16 2017-06-27 Addex Pharmaceuticals Sa derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
EP2391652A4 (en) 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
BR112012007365A2 (pt) 2009-10-15 2016-11-22 Abbott Lab proteínas de ligação à il-1
CN105056232A (zh) 2010-06-03 2015-11-18 阿布维生物技术有限公司 用于治疗化脓性汗腺炎(hs)的用途和组合物
US20110311547A1 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis Treatment
KR20210128021A (ko) 2010-08-23 2021-10-25 얀센 바이오테크 인코포레이티드 종양성 질병들에 대한 치료
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
HRP20180421T1 (hr) * 2010-11-17 2018-04-20 Chugai Seiyaku Kabushiki Kaisha Višestruko specifične molekule za vezanje na antigen koje imaju alternativnu funkciju u odnosu na funkciju faktora viii zgrušavanja krvi
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Il-1結合蛋白
AU2012228769B2 (en) * 2011-03-14 2016-09-08 Phlogo Aps Antagonists of the interleukin- 1 receptor
AU2012236106B2 (en) 2011-04-01 2016-12-08 Janssen Biotech, Inc. Treatment for dermatological pathologies
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
MX376241B (es) 2012-10-04 2025-03-06 Xbiotech Inc Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.
WO2014055541A1 (en) * 2012-10-04 2014-04-10 Xbiotech, Inc. Treatment of psychiatric conditions
US9809645B2 (en) * 2013-03-12 2017-11-07 Zenyaku Kogyo Kabushikikaisha Anti-Staphylococcus antibody, method for manufacturing same, and usage of same
US20150024031A1 (en) 2013-07-17 2015-01-22 Baxter International Inc. Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
US9416172B2 (en) 2014-06-03 2016-08-16 Xbiotech, Inc. Compositions and methods for treating and preventing Staphylococcus aureus infections

Similar Documents

Publication Publication Date Title
JP2020507587A5 (enExample)
François et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial
JP2022188083A5 (enExample)
JP2017113019A5 (enExample)
JP2018193377A5 (enExample)
JP2015534578A5 (enExample)
JP2014533279A5 (enExample)
JP2017512193A5 (enExample)
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
JP2017503820A5 (enExample)
JP2011500843A5 (enExample)
JP2015534579A5 (enExample)
Liang et al. RETRACTED ARTICLE: Curcumin inhibits the migration of osteoclast precursors and osteoclastogenesis by repressing CCL3 production
JP2016501892A5 (enExample)
RU2018123717A (ru) Комбинированные лечения, их применения и способы
JP2017149726A5 (enExample)
JP2012121878A5 (enExample)
JP2011184466A5 (enExample)
JP2015505564A5 (enExample)
JP2013518912A5 (enExample)
JP2012046518A5 (enExample)
Garrido et al. Medical course and complications after lung transplantation
JP2010500370A5 (enExample)
WO2015191568A3 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
JP2006514636A5 (enExample)